Iovance commences LN-145 dosing in Phase II trial for cervical cancer
US-based biotechnology firm Iovance Biotherapeutics has commenced patient dosing in its Phase II C-145-04 clinical trial of LN-145 to treat recurrent, metastatic or persistent cervical carcinoma.
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news
More News: Biotechnology | Cancer | Cancer & Oncology | Carcinoma | Cervical Cancer | Clinical Trials | Pharmaceuticals